Abstract
HERPESVIRUS infections remain among the most troublesome afflictions facing patients and clinicians. Although "remedies" for herpes infections have long been with us, until recently none has withstood close scrutiny. Since this subject was last reviewed in the Journal,1 a number of well-controlled clinical trials of anti-herpes agents have been conducted. Moreover, both topical and intravenous preparations of acyclovir have been licensed in the United States, and licensure of oral acyclovir is on the horizon. Other anti-herpes nucleoside derivatives and a multitude of different interferon preparations are under trial. Physicians have gone from a situation in which there was no . . .
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
